Comparative study of two prostaglandins inhibiting adenosine diphosphate-induced platelet aggregation in vitro
XIA Qing1, LI Yi2, LI Wei1, HU Huijing2, CHEN Yun2, RUAN Jingxiong3
1. Department of Pharmacy, Air Force No.986 Hospital,Xi’an 710054,China; 2.Xi’an Libang Zhaoxin Biotechnology Limited Company,Xi’an 710077,China; 3. Department of Clinical Laboratory, the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China
Abstract：ObjectiveTo investigate the inhibitory effects of two types of prostaglandins(epoprostenol sodium and prostaglandin E1) on adenosine diphosphate (ADP)-induced platelet aggregation in vitro.Methods Platelet suspension was incubated with epoprostenol sodium and prostaglandin E1 respectively at different concentrations(0, 50, 125, 500 and 2500 ng/ml)before the maximal extent of platelet aggregation was determined at the best ADP concentration and the best incubation time.Results At 20 μM ADP and after incubation of 5 min, the platelet aggregation of both types of prostaglandins induced by ADP was reduced accordingly with the increase of the concentrations of epoprostenol sodium and prostaglandin E1. The inhibitory rate of platelet aggregation induced by epoprostenol sodium was 19.61%, 48.13%, 88.25%, 93.71%, and 100% respectively,compared with 5.20%, 11.70%, 23.16%, 28.10% and 65.09% respectively for prostaglandin E1.Conclusions Epoprostenol sodium and prostaglandin E1 can inhibit ADP-induced platelet aggregation in a concentration-dependent manner in vitro, and the former is more effective.
Weiss H J, Turitto V T. Prostacyclin (Prostaglandin I2, PGI2) inhibits plat-elet adhesion and thrombus formation on subendothelium[J], Blood, 1979, 53(2): 244-250.
[2]
O’Connell C, Amar D, Boucly A, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension[J], Drug Saf, 2016, 39(4): 287-294.
[3]
Akagi S, Nakamura K, Matsubara H, et al. Epoprostenol therapy for pulm-onary arterial hypertension[J], Acta Med Okayama, 2015, 69(3): 129-136.
[4]
Chin K M, Badesch D B, Robbins I M, et al. Two formulations of epoprostenol sodium in the trea tment of pulmonary arterial hypertension: PITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), aphase Ⅳ, open-label, randomized study[J]. Am Heart J, 2014, 167(2): 218-225.
Madelene Lindkvist,Ulrika Fernberg,Liza U. Individual variations in platelet reactivity towards ADP, epinephrine, collagen and nitric oxide, and the association to arterial function in young, healthy adults[J]. Thromb Res, 2019, 174: 5-12.
2020, Vol. 31 
